Calls for papers
Cardiology special issue: July 6 is the submission deadline for a special issue ahead of the ESC Congress in Barcelona (Aug 29–Sept 2).
|
||
A Leading Edge article in The Lancet Infectious Diseases unravels the confusion between scientific uncertainty and hype, and a TLID Newsdesk article reports on plans for seasonal vaccination manufacture and incorporation of H1N1. The Lancet also reports on the background, spread, and treatment of swine influenza in an Editorial, a World Report, and a Comment. Many of these issues are discussed in a special influenza podcast. |
RECORD 4 study
Article The Lancet (online May 5)
|
Breast-tissue composition and cancer
Article The Lancet Oncology (online April 30)
|
Cystic fibrosis
Seminar The Lancet (online April 28)
|
The US Institute of Medicine's Committee on Conflict of Interest in Medical Research, Education, and Practice has published its final report. It stresses the importance of preventing bias, rather than tackling its consequences, and includes tips for identifying, limiting, and managing conflicts without damaging research collaborations.
Russia is facing human development obstacles that go beyond the economic and social, according to a UNDP report. A demographic challenge has arisen from Russia's low birth rate, ageing population, short life expectancies, and unclear immigration policies. The report cites the need for knowledge, political will, and economic resources in management of this problem.
Drug company Crucell N V and the Aeras Global TB Vaccine Foundation have started a phase I trial to test the safety of their jointly developed tuberculosis vaccine in infants previously immunised with the bacille Calmette-Guérin vaccine. The trial, the first in infants, is being done in South Africa in 54 healthy infants who have not been exposed to tuberculosis or HIV/AIDS.
The incidence of HIV in Taiwan's population of injection-drug users (IDUs) has decreased by almost 50% over 3 years. 3300 new cases were reported in 2005 compared with 1752 in 2008. This success is attributed to the country's harm-reduction programme, launched in 2006, which incorporates screening of IDUs, a needle-exchange scheme, and the use of methadone.
More This Week in Medicine:
1. |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial
Article (2009) Lancet 373 (9672), pp. 1341-1351
|
2. |
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Article (2009) Lancet 373 (9670), pp. 1175-1182
|
3. |
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Article (2009) Lancet 373 (9669), pp. 1083-1096
|
4. |
Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials
Article (2009) Lancet 373 (9670), pp. 1190-1197
|
5. |
A girl with episodic abdominal pain
Clinical Picture (2007) Lancet 369 (9576), p. 1890
|
1. | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Research (1998) Lancet 352 (9131), pp. 837-853
|
2. | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial
Research (2002) Lancet 360 (9326), pp. 7-22
|
3. | Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
Research (1998) Lancet 351 (9118), pp. 1755-1762
|
4. | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
Research (1996) Lancet 348 (9038), pp. 1329-1339
|
5. | Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
Research (2001) Lancet 358 (9286), pp. 958-965
|